NCT03931291 trial: what clinicians have said so far
APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant
- NCT03931291 ↗
- Completed
- Aprea Therapeutics
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on NCT03931291 (eprenetapopt plus azacitidine in TP53-mutant AML or MDS following allogeneic stem-cell transplant) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03931291 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- Phase II Trial of APR-246 in Combination With Azacitidine as Maintenance Therapy for TP53 Mutated AML or MDS Following Allogeneic Stem Cell Transplant
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Acute Myeloid Leukemia or Myelodysplastic Syndromes
- Interventions
- APR-246
- Arms
- Experimental arm: APR-246 + azacitidine · Experimental
- Enrollment
- 33
- Primary outcomes
- To Assess Relapse-free Survival (RFS) in Patients With TP53 Mutated AML or MDS After Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HSCT).
- Sponsor
- Aprea Therapeutics
- Start
- Sep 16, 2019
- Primary completion
- Aug 27, 2021
- Results posted
- Yes
- Registry record
- NCT03931291 · updated Mar 17, 2025
Publications
linked from the registry- Mishra A, Tamari R, DeZern AE, Byrne MT, Gooptu M, Chen YB, Deeg HJ, Sallman D, Gallacher P, Wennborg A, Hickman DK, Attar EC, Fernandez HF. Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Clin Oncol. 2022 Dec 1;40(34):3985-3993. doi: 10.1200/JCO.22.00181. Epub 2022 Jul 11. PubMed 35816664